(via TheNewswire)
Under the terms of the MOU, Egret and Alvarius intend toelucidate the biosynthetic pathways leading to the entourage of tryptamines (5-MeO-DMT, 5-MeO-tryptamine, 5-HO-N-methyltryptamine, Bufotenin and DMT) produced in the toads’ parotoid glands secretions. Alvarius recently commenced an ex situ conservation program with eight individual toads from two independent captive populations and have developed ethical means to harvest parotoid gland secretions. The latter are in the process ofbeing chemically characterized via tryptamine profiling using the Egret High Pressure Liquid Chromatography (HPLC) assay and will be used to record intra-individual variation in tryptamine profiles with the goal of identifying individuals to set up future breeding populations.
Subsequent research will investigate genes uniquely expressed in parotoid glands. A reference genome will be assembled with the ultimate goal toenhance ethical and humane ex situ conservation programs and to develop genomic resources to assist the conservation of the species in the wild. The teams will also jointly develop an alternative to synthetic toad-free tryptamine production using a cell-based culture pipeline to produce the compounds of interest while retaining the natural entourage. Such compounds have shown promise in the treatment of a variety of indications including cluster headaches, and major depressive disorder.
“We are excited to move forward with this significant project.
“This collaboration with Egret carries multiple dimensions of beneficial impact,” stated
Click Image To View Full Size
Mugshot of “Little Buddha” one of the 7 year old Colorado river toads in the Alvarius’ terrarium at
For more information and to subscribe to the Company’s mailing list, please visit https://lexston.ca/contact/.
About
On Behalf of the Board of Directors
Telephone: (604) 928-8913
Forward-Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Copyright (c) 2022 TheNewswire - All rights reserved.
Copyright (c) 2022 TheNewswire - All rights reserved., source